Ignite Creation Date:
2024-10-25 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06554574
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-12
Brief Title:
A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Sequential Randomized Double-Blind Placebo-Controlled Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally to Evaluate the Safety Tolerability and Pharmacokinetics in Healthy Male and Female Participants 18 to 55 Years of Age
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a sequential randomized double-blind placebo-controlled Phase 1 single SAD and multiple MAD ascending dose study to evaluate the safety tolerability and pharmacokinetics PK of orally administered LTG-001 in healthy male and female participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None